Clinical trials: Fibromyalgia
Fibromyalgia
A Safety Study Of Pregabalin In Fibromyalgia
To evaluate the safety of pregabalin in patients with fibromyalgia.
- Trial name
- NCT00282997
- Testing
- pregabalin
- Where
- 72 sites in United States
- Volunteers
- 500 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Fibromyalgia
This Study is An Open-Label Trial Of Pregabalin In Patients With Fibromyalgia
The main purpose of this protocol is to evaluate the long-term safety of pregabalin in patients who participated in the previous fibromyalgia Study A0081100 and who wish to receive open-label pregabalin therapy.
- Trial name
- NCT00346034
- Testing
- Pregabalin
- Where
- 51 sites in Canada, Denmark and 10 more
- Volunteers
- 357 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Fibromyalgia
An fMRI Study Of Brain Response In Patients With Fibromyalgia
The purpose of this study is to explore how pregabalin works in patients with fibromyalgia by evaluating brain imaging signals. To find out whether fMRI (functional magnetic resonance imaging) is an efficient way to show whether…
- Trial name
- NCT00760474
- Where
- 2 sites in United States
- Volunteers
- 27 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Fibromyalgia
Study Of A Controlled Release Formulation Of Pregabalin In Fibromyalgia Patients
The purpose of this study is to evaluate the efficacy and safety of a controlled release formulation of pregabalin administered once daily as compared to placebo in the treatment of fibromyalgia.
- Trial name
- NCT01271933
- Testing
- pregabalin
- Where
- 52 sites in United States, Canada and 2 more
- Volunteers
- 441 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Fibromyalgia
A Phase 3b Multicenter Study of Pregabalin in Fibromyalgia Subjects Who Have Comorbid Depression
The intent of this study is to identify and treat fibromyalgia subjects with comorbid depression who are receiving an SSRI (selective serotonin reuptake inhibitor) or SNRI (selective norepinephrine reuptake inhibitor) primarily…
- Trial name
- NCT01432236
- Testing
- Pregabalin
- Where
- 37 sites in United States, Canada and 2 more
- Volunteers
- 197 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
ADHD, Fibromyalgia
TD-9855 Mass Balance Study
The purpose of the study is to evaluate the absorption, distribution, metabolism, and excretion (ADME) of a single oral dose of [14C]TD-9855
- Trial name
- NCT01924143
- Testing
- TD-9855
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Theravance Biopharma
Fibromyalgia
Safety Study of DS-5565 for Treatment of Fibromyalgia Pain in Subjects With Chronic Kidney Disease
DS-5565 (mirogabalin) is being studied as treatment for fibromyalgia (FM) pain. Because it is excreted through the kidneys, people who have reduced kidney function will not process the drug as well as with those with normal…
- Trial name
- NCT02496884
- Testing
- DS-5565
- Where
- 39 sites in United States, Bulgaria and 6 more
- Volunteers
- 56 people
- Sponsor
- Daiichi Sankyo
Pain Associated With Fibromyalgia
Treatment of Pain Associated With Fibromyalgia
The main objective of this trial is to compare change in weekly average daily pain score (ADPS) from baseline to Week 13 in subjects receiving either dose of DS-5565 versus placebo.
- Trial name
- NCT02146430
- Testing
- DS-5565, Pregabalin
- Where
- 165 sites in United States, Canada and 9 more
- Volunteers
- 1,293 people
- Sponsor
- Daiichi Sankyo
Pain Associated With Fibromyalgia
Treatment of Pain Associated With Fibromyalgia
The main objective of this trial is to compare change in weekly average daily pain score (ADPS) from baseline to Week 13 in participants receiving either dose of DS-5565 versus placebo.
- Trial name
- NCT02187159
- Testing
- DS-5565, Pregabalin
- Where
- 176 sites in United States, Australia and 10 more
- Volunteers
- 1,270 people
- Sponsor
- Daiichi Sankyo
Pain Associated With Fibromyalgia
Treatment of Pain Associated With Fibromyalgia
The main objective of this trial is to compare change in weekly average daily pain score (ADPS) from baseline to Week 13 in participants receiving either dose of DS-5565 versus placebo.
- Trial name
- NCT02187471
- Testing
- DS-5565, Pregabalin
- Where
- 154 sites in United States, Argentina and 12 more
- Volunteers
- 1,301 people
- Sponsor
- Daiichi Sankyo
Pain Associated With Fibromyalgia
An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
This is an open-label study of DS-5565 in subjects who either completed participation in a preceding Phase 3 study of DS-5565 in fibromyalgia (FM); i.e.
- Trial name
- NCT02234583
- Testing
- DS-5565
- Where
- 276 sites in United States, Australia and 27 more
- Volunteers
- 2,485 people
- Sponsor
- Daiichi Sankyo
Fibromyalgia
Use of a Probiotic in the Treatment of Fibromyalgia (FIBROPROB)
This study aims to understand the efficacy of two probiotic interventions as prophylaxes of fibromyalgia symptoms in individuals diagnosed.
- Trial name
- FIBROPROB (NCT04435886)
- Testing
- Probiotic
- Where
- Spain
- Volunteers
- 50 people
- Sponsor
- Biopolis S.L.
Fibromyalgia, Cannabis
Phase II Clinical Trial, Use of KL16-012 in Women With Fibromyalgia Refractary to Conventional Treatment.
A double blind randomized placebo controlled trial in 44 women with fibromyalgia and persistent symptoms in spite of use of conventional pharmacotherapy, will be performed in the city of Valparaiso.
- Trial name
- NCT04239469
- Testing
- KL16-012
- Volunteers
- 44 people
- Sponsor
- Knop Laboratorios
Fibromyalgia
Open Label Extension Study of [S,S]-Reboxetine in Patients With Fibromyalgia
This is a study to investigate the long-term safety and effectiveness [S,S]-Reboxetine in relieving the symptoms of Fibromyalgia in patients.
- Trial name
- NCT00754221
- Testing
- [S,S]-Reboxetine
- Where
- 109 sites in United States, Canada
- Volunteers
- 390 people
- Sponsor
- Pfizer
Fibromyalgia
Long-term OL Study of [S,S]-RBX in Patients With Fibromyalgia
To evaluate the lon-term safety and tolerability of [S,S]-reboxetine in patients with fibromyalgia
- Trial name
- NCT00607256
- Testing
- [S,S]-reboxetine
- Where
- 79 sites in United States, Belgium and 9 more
- Volunteers
- 500 people
- Sponsor
- Pfizer
Fibromyalgia
A 14-week, Multi-center Study of [S,S]-Reboxetine in Patients With Fibromyalgia.
This is a study to investigate the effectiveness and safety of [S,S]-Reboxetine in relieving the symptoms of Fibromyalgia in patients.
- Trial name
- NCT00612170
- Testing
- [S,S]-Reboxetine
- Where
- 145 sites in United States, Canada
- Volunteers
- 1,129 people
- Sponsor
- Pfizer
Fibromyalgia
A Study for Adolescents With Fibromyalgia Syndrome
The purpose of this study is to evaluate the possibility of conducting a larger study in adolescents with fibromyalgia syndrome.
- Trial name
- NCT01089621
- Testing
- Duloxetine
- Where
- 9 sites in United States
- Sponsor
- Eli Lilly and Company
Fibromyalgia
A Study of Duloxetine in Adolescents With Juvenile Primary Fibromyalgia Syndrome
The purpose of this study is to determine whether duloxetine is safe and effective in the treatment of adolescents with Juvenile Primary Fibromyalgia Syndrome (JPFS). This trial consists of two distinct study periods.
- Trial name
- NCT01237587
- Testing
- Duloxetine
- Where
- 33 sites in United States, Argentina and 2 more
- Volunteers
- 184 people
- Sponsor
- Eli Lilly and Company
Fibromyalgia
Cefaly® Device in the Treatment of Patients With Fibromyalgia.
The objective of this pilot open trial was to assess the efficacy and safety of external trigeminal nerve stimulation (e-TNS) with the Cefaly® device in fibromyalgia.
- Trial name
- NCT02546362
- Testing
- Cefaly
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Cefaly Technology
Primary Fibromyalgia
Safety and Efficacy of Milnacipran in Pediatric Patients With Primary Fibromyalgia
The purpose of this study is to evaluate the safety, tolerability, efficacy, and pharmacokinetics of milnacipran in pediatric patients aged 13 to 17 years with primary fibromyalgia.
- Trial name
- MyFi (NCT01328002)
- Testing
- Milnacipran
- Where
- 47 sites in United States
- Volunteers
- 116 people
- Sponsor
- Forest Laboratories